Corrigendum to “Factors regulating dynamics of angiotensin-converting enzyme-2 (ACE2), the gateway of SARS-CoV-2: Epigenetic modifications and therapeutic interventions by epidrugs” Biomed. Pharmacother. 143 (2021) 112095 - 23/05/23
Doi : 10.1016/j.biopha.2023.114796
Suvasmita Rath a, Venkateswarlu Perikala a, Atala Bihari Jena b, Jagneshwar Dandapat b, c, ⁎ 
a Centre of Environment, Climate Change and Public Health, Utkal University, Vani Vihar, Bhubaneswar 751004, Odisha, India
b Centre of Excellence in Integrated Omics and Computational Biology, Utkal University, Bhubaneswar 751004, Odisha, India
c Post-Graduate Department of Biotechnology, Utkal University, Bhubaneswar 751004, Odisha, India
⁎Corresponding author.
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Il testo completo di questo articolo è disponibile in PDF.
© 2023
Pubblicato da Elsevier Masson SAS.
Vol 163
Articolo 114796- Luglio 2023 Ritorno al numero
Articolo precedente
- The F/B ratio as a biomarker for inflammation in COVID-19 and T2D: Impact of metformin
- Pavlo Petakh, Valentyn Oksenych, Aleksandr Kamyshnyi
- Corrigendum to “PBMCs gene expression signature of advanced cirrhosis with high risk for clinically significant portal hypertension in HIV/HCV coinfected patients: A cross-control study” [Biomed. Pharmacother. 159 (2023) 114220]
- Sergio Salgüero, Óscar Brochado-Kith, Ana Virseda Verdices, Juan Berenguer, Juan González-García, Isidoro Martínez, Cristina Díez, Víctor Hontañón, Leire Pérez-Latorre, Amanda Fernández-Rodríguez, María Ángeles Jiménez-Sousa, Salvador Resino
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.